ATE429246T1 - Verfahren zur herstellung von biologischen produkten in protein-freiem kultur - Google Patents

Verfahren zur herstellung von biologischen produkten in protein-freiem kultur

Info

Publication number
ATE429246T1
ATE429246T1 AT01130212T AT01130212T ATE429246T1 AT E429246 T1 ATE429246 T1 AT E429246T1 AT 01130212 T AT01130212 T AT 01130212T AT 01130212 T AT01130212 T AT 01130212T AT E429246 T1 ATE429246 T1 AT E429246T1
Authority
AT
Austria
Prior art keywords
viruses
viral
producing
protein
free culture
Prior art date
Application number
AT01130212T
Other languages
German (de)
English (en)
Inventor
Otfried Kistner
Noel Barret
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/487,046 external-priority patent/US5753489A/en
Priority claimed from US08/483,522 external-priority patent/US5756341A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE429246T1 publication Critical patent/ATE429246T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01130212T 1994-11-10 1995-11-10 Verfahren zur herstellung von biologischen produkten in protein-freiem kultur ATE429246T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33876194A 1994-11-10 1994-11-10
US48722295A 1995-06-07 1995-06-07
US08/487,046 US5753489A (en) 1994-11-10 1995-06-07 Method for producing viruses and vaccines in serum-free culture
US08/483,522 US5756341A (en) 1994-11-10 1995-06-07 Method for controlling the infectivity of viruses

Publications (1)

Publication Number Publication Date
ATE429246T1 true ATE429246T1 (de) 2009-05-15

Family

ID=27502591

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95937888T ATE542891T1 (de) 1994-11-10 1995-11-10 Verfahren zur herstellung von biologischen produkten in protein-freier kultur
AT01130212T ATE429246T1 (de) 1994-11-10 1995-11-10 Verfahren zur herstellung von biologischen produkten in protein-freiem kultur

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95937888T ATE542891T1 (de) 1994-11-10 1995-11-10 Verfahren zur herstellung von biologischen produkten in protein-freier kultur

Country Status (10)

Country Link
EP (3) EP2290053A1 (xx)
JP (1) JP3158157B2 (xx)
AT (2) ATE542891T1 (xx)
CA (2) CA2415990C (xx)
DE (1) DE69535940D1 (xx)
DK (2) DK0791055T3 (xx)
ES (2) ES2323490T3 (xx)
FI (1) FI121117B (xx)
HK (1) HK1002285A1 (xx)
WO (1) WO1996015231A2 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
DE19655440B4 (de) * 1996-04-01 2013-09-05 Novartis Vaccines And Diagnostics Gmbh Verfahren zur Herstellung eines Influenzaimpfstoffs
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US6110724A (en) * 1996-10-18 2000-08-29 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001011021A1 (de) * 1999-08-05 2001-02-15 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
EP1211309A4 (en) * 1999-08-20 2003-02-12 METHOD AND DEVICE FOR PROPAGING HEPATITISVIRUS
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
WO2004005493A1 (en) 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
NZ538575A (en) 2002-09-05 2007-03-30 Bavarian Nordic As Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
EP1739167B1 (en) 2004-04-19 2015-08-12 DENKA SEIKEN Co., Ltd. Method of producing virus
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20070101326A (ko) * 2005-01-14 2007-10-16 로버트 알렉산더 바이러스 회복 배지, 이의 사용 및 이를 포함하는 바이러스진단 키트
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2522717B1 (en) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptide-free cell culture media
EP1982727A1 (en) * 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
KR101258949B1 (ko) 2007-06-15 2013-04-30 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
DK2373783T3 (da) 2008-12-30 2018-01-29 Baxalta GmbH Fremgangsmåde til at forbedre cellevækst under anvendelse af alkyl-amin-n-oxid (aanox)
WO2010079081A1 (en) * 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
JP2012525830A (ja) * 2009-05-08 2012-10-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 均質化を含む細胞培養からのウイルスの製造方法
PT2459702T (pt) 2009-07-31 2016-08-02 Baxalta Inc Meio de cultura de células para a expressão da proteína adamts
WO2011145081A1 (en) * 2010-05-21 2011-11-24 Novartis Ag Influenza virus reassortment method
AU2015258263B2 (en) * 2010-05-21 2017-12-07 Seqirus UK Limited Influenza virus reassortment method
SI2591094T1 (sl) 2010-07-08 2018-12-31 Baxalta GmbH Metoda proizvodnje rekombinantnih ADAMTS13 v celični kulturi
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
EP2867359B1 (en) 2012-06-29 2021-09-15 EMD Millipore Corporation Methods for inactivating viruses during a protein purification process
CN104755606B (zh) 2012-08-31 2019-04-12 阿尔伯达大学董事会 用于产生具有原代人肝细胞表型的细胞的方法和组合物
WO2015101510A1 (en) 2013-12-30 2015-07-09 Baxter Healthcare Sa A method of predicting a performance characteristic of a plant or yeast hydrolysate and its use
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
WO2018012498A1 (ja) * 2016-07-15 2018-01-18 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルス作出方法
KR101869010B1 (ko) 2016-09-09 2018-06-20 주식회사 포스코 이물 제거장치
EP3677672A4 (en) * 2017-08-28 2021-06-09 The Research Foundation for Microbial Diseases of Osaka University METHOD ALLOWING THE GRADUAL CONSTRUCTION OF A REASSORTED INFLUENZA VIRUS
WO2020004425A1 (ja) * 2018-06-27 2020-01-02 一般財団法人阪大微生物病研究会 インフルエンザウイルスの培養方法
RU2738404C1 (ru) * 2019-08-26 2020-12-11 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ инактивации культурального ротавируса человека

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
GB8300467D0 (en) * 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
JPH04228066A (ja) * 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen

Also Published As

Publication number Publication date
FI121117B (fi) 2010-07-15
EP0791055B1 (en) 2012-01-25
WO1996015231A2 (en) 1996-05-23
JPH10503093A (ja) 1998-03-24
CA2415990A1 (en) 1996-05-23
CA2205015C (en) 2003-04-08
EP1213030B1 (en) 2009-04-22
EP1213030A1 (en) 2002-06-12
ES2378409T3 (es) 2012-04-12
EP2290053A1 (en) 2011-03-02
ATE542891T1 (de) 2012-02-15
HK1002285A1 (en) 1998-08-14
DK0791055T3 (da) 2012-04-16
CA2415990C (en) 2009-07-07
FI971998A (fi) 1997-05-09
DE69535940D1 (de) 2009-06-04
ES2323490T3 (es) 2009-07-17
EP0791055A1 (en) 1997-08-27
WO1996015231A3 (en) 1996-08-01
CA2205015A1 (en) 1996-05-23
JP3158157B2 (ja) 2001-04-23
FI971998A0 (fi) 1997-05-09
DK1213030T3 (da) 2009-07-20

Similar Documents

Publication Publication Date Title
ATE429246T1 (de) Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DK1108787T4 (da) Fremstilling af vacciner
DE69740002D1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE69838383D1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
ATE125157T1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE270342T1 (de) Endosomolytisch wirksame partikel
ATE384785T1 (de) Herstellung von viren, virusisolaten, und impfstoffen
ATE414146T1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav- vektoren mit hohem titer
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
NO20032097L (no) Gj¶ravledet vaksine mot IPNV
ATE184915T1 (de) Verfahren zur herstellung von vakzinen und ihre verwendung
CY1108849T1 (el) Πολλαπλασιαμος του ιου κορωνα των βοοειδων σε κυτταρα ωοθηκων κινεζικων κρικητων
WO1997027742B1 (en) Method of protein production using mitochondrial translation system
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
DE69032453D1 (de) Expressionsvektoren und verfahren zur herstellung intrazellularer proteine
DE69535716D1 (de) Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
DE69021879D1 (de) Verfahren zur herstellung von impfstoffen gegen rna-virus.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1213030

Country of ref document: EP